P-21: FDA Status and Evidence
An experimental compound studied in animal models of Alzheimer's disease. It is not FDA-approved, and no human trials have been published.
Medically reviewed by Charles Kamen, MD, board-certified neurologist · ·
What the research shows
P021 is a small peptide-derived compound based on ciliary neurotrophic factor. It has been studied in mouse models of Alzheimer's disease and aging. No human trials have been published.
Frequently Asked Questions
Is P-21 FDA-approved?
No. P-21 has never been approved by FDA.
Can a pharmacy compound P-21?
It is not on FDA's bulk-substance lists for compounding.
Has P-21 been tested in humans?
No human trials have been published. The evidence is from animal studies.
Related Cognitive & neurological support
DSIP (Delta Sleep-Inducing Peptide)
A peptide studied for sleep and stress regulation - supervised by a board-certified neurologist in Las Vegas.
Semax
A peptide studied for cognition and focus - supervised by a board-certified neurologist in Las Vegas.
Selank
A peptide studied for calm focus and stress resilience - supervised by a board-certified neurologist in Las Vegas.
Dihexa
A peptide studied for memory and synaptic connections - supervised by a board-certified neurologist in Las Vegas.